NMN tracker
Educational reference for NMN. Use it inside TrackPep to log doses, side effects, and rotation sites.
Half-life
—
Tmax
—
Category
other
Also known as: nicotinamide-mononucleotide
> PLACEHOLDER — pending clinical review by licensed pharmacist. NMN (nicotinamide mononucleotide) is an NAD+ precursor used as a longevity supplement. Not a drug; supplement use.
Mechanism
Nicotinamide mononucleotide (NMN) is a NAD+ precursor. In preclinical research, supplying NMN is associated with raising NAD+ levels and supporting NAD+-dependent processes; the extent and clinical relevance in humans are still being studied.
Research summary
Preclinical studies suggest metabolic effects, and some small human trials have examined tolerability and biomarkers. Clinical outcome evidence is still developing, and its regulatory status as a supplement has been subject to change in some jurisdictions. It is not an approved drug for specific indications.
Dosing in the literature
Small human studies have used oral administration; robust dose-response data for clinical outcomes are limited. This summary does not provide dosing.
Reported side effects
Small trials have generally reported good tolerability, but long-term human safety data are limited.
Stacking notes
Discussed alongside other NAD+ precursors (NR) and longevity-related cofactors; controlled human outcome evidence for combinations is limited.
Educational summary of published research. Not dosing guidance or medical advice.
Sources
- NMN human tolerability and biomarker studies · peer-reviewed clinical studies (2021)search PubMed for NMN human trial
- NAD+ precursor review · peer-reviewed review article (2020)class context; clinical outcomes still developing
Track NMN in TrackPep
Reconstitution calculator, interactive body-map rotation, side-effect timeline, weight trends, and a private log — all in one place. Free to try.